GRDN at a glance
Guardian Pharmacy Services, Inc. (GRDN, SEC CIK 1802255) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Guardian Pharmacy Services, Inc. (GRDN) reported revenue of $1.4 billion (up 17.9% from FY2024) and net income of $49.2 million.
- The most recent insider open-market sale reported on Form 4 was by Martin David Norman on November 17, 2026 of 200 shares at $50.58 per share.
- In the last 90 days, GRDN insiders reported 0 open-market purchases ($0) and 4 open-market sales ($503K) on Form 4, a net sale of $503K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.4B
- +17.9% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$503K
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Regulatory risk: existing 10-K risks remain applicable to pharmacy operations
- Operational risk: carried-forward 10-K risks could adversely affect business and results
- Financial risk: existing 10-K risks could adversely affect financial condition and prospects
- Market risk: carried-forward risks could reduce Class A common stock price
Management Discussion & Analysis
- Q3 revenue $371.1M, down 1.7% from $377.4M, reflecting IRA-related pricing reductions
- Gross margin 23.0% vs 19.8%; net margin 5.2% vs 2.5% YoY
- Acquisitions strongest contributor, adding $7.3M revenue; organic revenue decreased $13.7M
- Cash $119.7M; nine-month operating cash flow $79.5M vs $65.7M, up $13.8M
- IRA price reductions remain a headwind, expected to affect year-over-year comparability through the remainder of 2026
AI summary of the GRDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Guardian Pharmacy Services’ financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings figures and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $371.1M, down 2% YoY despite residents served increasing 7% to approximately 218,000, reflecting IRA pricing pressure
- Net income $19.1M versus $9.6M, while Adjusted EBITDA rose 24% to $33.9M and margin expanded to 9.1% from 7.2%
Item 8.01: Other Events
- Lock-ups cover approximately 29.9 million Class A shares held by founders, executives and employees
- Restricted shares represent approximately 81% of pre-IPO holders’ approximately 37 million shares
Item EX-99.1: Item EX-99.1
- Q2 revenue $351.8M, up 2%; residents served rose 8% to approximately 210,000
- Adjusted EBITDA $29.7M versus $25.0M; margin expanded to 8.4% from 7.2%
Item 2.02: Results of Operations and Financial Condition
- Press release announces Guardian Pharmacy Services’ financial results for quarter ended June 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, guidance and operating trends
AI summaries of GRDN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GRDN
Don't miss the next GRDN filing
- Alerts as it files. A push when GRDN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GRDN, by share count.
- Ask anything. An AI agent that reads every GRDN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Martin David Norman | Sell | Nov 17, 2026 | 200 | $50.58 |
| Martin David Norman | Sell | Nov 17, 2026 | 4,800 | $50.24 |
| Martin David Norman | Sell | Nov 17, 2026 | 4,800 | $50.24 |
| Martin David Norman | Sell | Nov 17, 2026 | 200 | $50.58 |
| Ackerman John | M | Sep 27, 2026 | 1,413,939 | - |
| Forbes Kendall | M | Sep 27, 2026 | 608,570 | - |
| Ackerman John | M | Sep 27, 2026 | 1,413,939 | - |
| Pharmacy Investors, LLC | M | Sep 27, 2026 | 1,413,939 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.4B |
| Gross Profit | - | $244.4M | $292.7M |
| Operating Income | - | -$62.9M | $72.7M |
| Net Income | - | -$110.0M | $49.2M |
| Gross Margin | - | 19.9% | 20.2% |
| Op. Margin | - | -5.1% | 5.0% |
| Net Margin | - | -9.0% | 3.4% |
| Balance Sheet | |||
| Total Assets | - | $320.8M | $412.7M |
| Equity | $59.9M | $150.0M | $217.9M |
| ROE | - | -73.4% | 22.6% |
| Cash Flow | |||
| Operating CF | - | $58.0M | $100.3M |
Source: XBRL data in Guardian Pharmacy Services, Inc. (GRDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
GRDN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | May 28, 2026 | - | Analysis |
Related Consumer Staples companies
- ACI · Albertsons Companies IncRetail-Grocery Stores
- MO · AltriaCigarettes
- ANDE · Andersons, Inc.Wholesale-Farm Product Raw Materials
- BUD · Anheuser-Busch InBev SA/NVMalt Beverages
- ADM · Archer Daniels MidlandFats & Oils
- ARKO · ARKO Corp.Retail-Convenience Stores
- BGS · B&G Foods, Inc.Food and Kindred Products
- BYND · BEYOND MEAT, INC.Food and Kindred Products
GRDN SEC filings: frequently asked questions
Are GRDN insiders buying or selling?
In the last 90 days, Guardian Pharmacy Services, Inc. (GRDN) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $502,536 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was GRDN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Guardian Pharmacy Services, Inc. (GRDN) reported revenue of $1.4 billion (up 17.9% from FY2024) and net income of $49.2 million. The figures come from the XBRL data in the 10-K.
What did GRDN report in its latest 8-K?
Guardian Pharmacy Services, Inc. (GRDN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Guardian Pharmacy Services’ financial results for quarter ended September 30, 2026.
What are the latest GRDN SEC filings?
Guardian Pharmacy Services, Inc. (GRDN) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.
What is GRDN's SEC CIK number?
Guardian Pharmacy Services, Inc. (GRDN)'s SEC Central Index Key (CIK) is 1802255. EDGAR lists every GRDN filing under that number.
Ask anything about GRDN
The research agent reads GRDN's filings, financials, insider trades and 13F holders, then answers with sources.